Skip to main content

Review of rituximab in primary CNS lymphoma

Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients.

from Journal of the Neurological Sciences https://ift.tt/2ZswSGa
Labels:

Comments

Post a Comment

Popular posts from this blog

Reading Minds to Understand Human Tool Use

Combining brain imaging data with machine learning, researchers make new discoveries about how the brain controls the hand. The findings could lead to the development of more advanced neuroprosthetics. from Neuroscience News https://ift.tt/3tv7BbC
Post a Comment
Read more

Rethinking the Link Between Cannabinoids and Learning

Disrupted cannabinoid signaling impairs learning by altering behavioral states. from Neuroscience News https://ift.tt/2Hrmr0g
Post a Comment
Read more